Tandem Diabetes Care reports developments in automated insulin delivery and diabetes technology. The company manufactures and sells pump systems including Tandem Mobi and the t:slim X2 insulin pump, both powered by Control-IQ+ advanced hybrid closed-loop technology. News commonly covers FDA clearances, pump and mobile-app compatibility, continuous glucose monitoring integrations, and product portfolio updates for people with diabetes.
Company updates also address quarterly and annual operating results, worldwide and U.S. sales trends, pump shipments, gross margin, financial guidance, reimbursement-model changes, investor conference presentations, and capital actions such as convertible debt financing.
Tandem Diabetes Care (Nasdaq: TNDM), a leading insulin delivery and diabetes technology company, has announced its participation in several upcoming investor conferences. The company will present updates and host meetings at the following events:
- 2024 Wells Fargo Healthcare Conference on September 5, 2024
- Morgan Stanley 22nd Annual Global Healthcare Conference on September 6, 2024
- Baird 2024 Global Healthcare Conference on September 11, 2024
- Lake Street Capital Markets 8th Annual Best Ideas Growth Conference on September 12, 2024
All presentations will be webcast live and archived for 30 days, accessible through Tandem Diabetes Care's Investor Center website.
Tandem Diabetes Care (Nasdaq: TNDM) has announced the release of version 2.8.2 of its Apple iOS t:connect mobile app on August 20, 2024. This update aims to address a battery depletion issue in t:slim X2 insulin pumps, which was the subject of a March 2024 recall. The problem can cause rapid battery drain, leading to unexpected pump shutdowns and potential health risks for users.
Key points:
- 143 confirmed adverse events, including two hospitalizations
- Update available in Apple App Store on August 20, 2024
- Impacted users urged to update their app immediately
- 24/7 technical support available for assistance
Tandem Diabetes Care (NASDAQ: TNDM) has provided an update on the March 2024 recall of its Apple iOS t:connect mobile app in the United States. The recall addresses an issue causing rapid depletion of t:slim X2 insulin pump batteries, potentially leading to unexpected pump shutdowns. Despite the release of version 2.7.1 in March, some customers continue to experience problems. 107 confirmed adverse events, including two hospitalizations, have been reported. Tandem plans to release a new app version to address remaining issues.
Recommendations for affected users include:
- Continue using the pump and app as per the User Guide
- Charge the pump daily for 10-15 minutes
- Monitor battery levels closely
- Carry backup supplies
- Charge immediately upon receiving a low battery alert
Tandem Diabetes Care (Nasdaq: TNDM) released its Q2 2024 financial results and raised its full-year 2024 sales guidance. Key highlights include:
Sales: Worldwide GAAP sales increased by 13% to $221.9M, while non-GAAP sales rose 12% to $221.8M compared to Q2 2023. US shipments of insulin pumps surged 33% sequentially. However, international shipments fell by 6%.
New Products: The company launched the Tandem Mobi integrated with the Dexcom G7 CGM in the US and began the international rollout of Tandem Source. Additionally, enrollment for the Control-IQ pivotal study for type 2 diabetes was completed.
Financials: GAAP gross profit increased to $112.8M from $101.7M. However, the GAAP operating loss was $30.8M, and the GAAP net loss was $30.8M. Non-GAAP operating loss stood at $30.9M, and non-GAAP net loss was $30.9M.
Guidance: The company increased its full-year 2024 sales guidance, reflecting strong demand for its latest technologies.
Tandem Diabetes Care (Nasdaq: TNDM), a leading insulin delivery and diabetes technology company, has announced its participation in the Canaccord Genuity 44th Annual Growth Conference. The company's management will present an update on Tuesday, August 13, 2024, at 1:30 PM Eastern Time (10:30 AM Pacific Time).
The presentation will be webcast live and an archive recording will be available for 30 days afterwards. Interested parties can access the live webcast and archive through the 'Events & Presentations' section of Tandem Diabetes Care's Investor Center website at http://investor.tandemdiabetes.com.
Tandem Diabetes Care and Dexcom have announced that the t:slim X2 insulin pump with Dexcom G7 CGM compatibility has been authorized for sale by Health Canada. This integration makes it the only Automated Insulin Delivery (AID) system in Canada compatible with both Dexcom G7 and G6 CGM technologies. The updated software is expected to be commercially available this fall, with existing users receiving a free remote update.
Key features of the integration include:
- Dexcom G7's smaller, all-in-one sensor and transmitter
- 30-minute sensor warmup time
- 12-hour grace period for sensor replacement
- Increased connectivity with digital health apps
The t:slim X2 pump with Control-IQ technology is rated as the #1 AID system in Canada, offering customizable profiles and various infusion set options.
Tandem Diabetes Care (NASDAQ: TNDM) will release its second quarter 2024 financial results on Thursday, August 1, 2024, after the market closes. The company will hold a conference call and webcast at 4:30 pm Eastern Time (1:30 pm Pacific Time) on the same day to discuss the financial and operating results. The live webcast will be available on Tandem Diabetes Care's Investor Center website. An archived version of the webcast will be accessible for 30 days post-event.
Tandem Diabetes Care (NASDAQ: TNDM), a leader in insulin delivery and diabetes technology, has appointed Jean-Claude 'JC' Kyrillos as the new Executive Vice President and Chief Operating Officer, effective June 21, 2024. Kyrillos brings over 20 years of global executive leadership experience in medical devices, digital health, and healthcare management.
Kyrillos previously held key roles at Envista Holdings, Qualcomm Life, Becton Dickinson, and ResMed. He has also served as an independent board director at the San Diego Blood Bank. Tandem's CEO, John Sheridan, highlighted Kyrillos' extensive technical, operational, and leadership skills.
Kyrillos expressed enthusiasm for joining Tandem, focusing on expanding global operations and delivering profitable growth while advancing their mission to improve lives through innovative insulin delivery technologies.
Tandem Diabetes Care (NASDAQ: TNDM) is set to present early user insights on its new Tandem Mobi System at the American Diabetes Association’s 84th Scientific Sessions from June 21-24 in Orlando, Florida.
The Product Theater session, scheduled for June 22, will feature presentations by key medical experts on the benefits of Tandem Mobi, the world's smallest durable Automated Insulin Delivery (AID) system, and its Control-IQ algorithm. The presenters will discuss the system's unique wearability and potential to improve patient outcomes.
Additional poster presentations will cover various studies on the t:slim X2 insulin pump with Control-IQ Technology and the Tandem t:connect mobile application.
Tandem Diabetes Care will also exhibit at Booth #1621, showcasing the Tandem Mobi and t:slim X2 systems, both compatible with multiple Continuous Glucose Monitors (CGMs).
Tandem Diabetes Care announced the compatibility of its Tandem Mobi insulin pump with both Dexcom G7 and G6 CGM systems.
This integration enhances user flexibility, allowing choice in diabetes management. Tandem Mobi, the smallest automated insulin delivery system, launched in the U.S. earlier in 2023, offers greater discretion and comfort.
Users will receive free software updates for this feature via email. New pumps will ship with the updated software pre-loaded.
This move strengthens Tandem's partnership with Dexcom and builds on their decade-long collaboration in providing innovative diabetes solutions.